Safety
HLH, skin rash, pulmonary infections, pain
ADVERSE EVENTS, ADVERSE EFFECTS, PULMONARY INFECTIONS, ADVERSE EVENT
No grade 3 or higher adverse events were observed in any of the patients during the study. Two patients experienced pulmonary infections while undergoing treatment, but they were not attributed to ruxolitinib since they occurred before the initiation of treatment. Two patients experienced aggravated aminotransferase increased, which may have been caused by the worsening of HLH in addition to drug-related factors. Two patients experienced grade 1 pain in the extremities, and one patient experienced skin rash.Among these patients, adverse effects possibly related to the increased dose of ruxolitinib included two cases of extremity pain and one case of aminotransferase increased. However, no adverse events led to discontinuation of treatment and no other adverse effects were observed. Please refer to Adverse events possibly related to treatment.ALT, alanine aminotransferase; AST, aspartate aminotransferase.